Fact Sheet

# CAN-FITE BioPharma Ltd



**Can-Fite BioPharma** is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has 2 drug candidates in advanced stages of development, Piclidenoson for the treatment of Psoriasis, Low Syndrome, and Pets' Osteoarthritis, and Namodenoson for the treatment of advanced Liver Cancer, Pancreatic Cancer, and MASH. Piclidenoson and Namodenoson have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.

## Piclidenoson

Pivotal Phase III Psoriasis Study – enrollment ongoing: A registration plan with a pivotal Phase III study design was agreed upon with the FDA and EMA. The prior Phase III Comfort™ trial enrolled >400 patients with moderate-to-severe psoriasis. Patients treated with Piclidenoson had a statistically significant progressive improvement along the study period compared to placebo. Piclidenoson's excellent safety profile was comparable to that of placebo and better than Otezla, a leading oral psoriasis drug on the market.

Lowe Syndrome Phase II – to be initiated: Based on successful pre-clinical data, a Phase II study design has been completed, and preparatory work is underway for a clinical study in Lowe Syndrome, a rare genetic disease. Five patients will be treated for 12 months. FDA and EMA approvals for rare genetic diseases are fast and require clinical studies with a small number of patients.

Pets' Osteoarthritis – positive results from Vetbiolix Phase II study: Can-Fite entered a $325 million licensing deal with Vetbiolix for Piclidenoson in the treatment of osteoarthritis in pets. Vetbiolix is covering costs associated with studies and regulatory approval.

## Namodenoson

Pivotal Phase III in Advanced Liver Cancer – enrollment ongoing: A registration plan with a pivotal Phase III study design was agreed upon with the FDA and EMA. Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for the treatment of advanced liver cancer. Namodenoson is being evaluated as a 2nd or 3rd line treatment with the primary endpoint of improved overall survival. An interim analysis will be conducted after 50% of the planned 450 patients are enrolled and treated.

Exploratory Phase IIa in Pancreatic Cancer – enrollment ongoing: An exploratory open-label Phase IIa study to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy has reached over 50% enrollment.

MASH Phase IIb – enrollment ongoing: Namodenoson is in a Phase IIb MASH multicenter, randomized, double-blind, placebo-controlled study with biopsy-confirmed SLD and F1-3 fibrosis. The former Phase IIa study met all efficacy and safety endpoints.

## Corporate Partnerships – Current Out-Licensing Deals

| | | |
|---|---|---|
| ewopharma | Eastern Europe | *Psoriasis, Liver Cancer, MASH Pancreatic cancer* |
| Gebro Pharma | Spain, Switzerland, Austria | *Psoriasis* |
| CMS 康哲药业 CHINA MEDICAL SYSTEM | China, Taiwan, Hong Kong, Macao | *Psoriasis, Liver Cancer, MASH* |
| Chong Kun Dang Pharm | South Korea | *Liver Cancer, MASH* |
| KYONGBO Pharmaceuticals | South Korea | *Psoriasis* |
| cipher PHARMACEUTICALS INC | Canada | *Psoriasis* |
| VETBIOLIX | Global | *Pets Osteoarthritis* |

**$20M** received in upfront and milestone payments

**$130M** potential based on regulatory and sales milestones

### Typical Deal Structure

- Up-front money upon signing a distribution deal
- Regulatory milestone payments
- **Royalties (double-digits)**
- Sales milestone payments

## SELECT FINANCIALS

**Ticker: NYSE - CANF**
Shares Outstanding: 26.2 M ADSs
Market Cap: ~$10 M

**Therapeutic Target**
A3 adenosine receptor (A3AR)

**Pipeline Drugs**
- ✓ Small molecules
- ✓ Orally bioavailable
- ✓ Bind with high selectivity to the A3AR
- ✓ Over-expressed in inflammatory and cancer cells

**Proven Therapeutic Effect**
Efficacious in Phase II and Phase III studies

**Excellent Safety Profile**
Demonstrated in >1,600 patients

## Analyst Coverage

H.C. WAINWRIGHT & CO.
Price Target $18.00

D. BORAL CAPITAL
Price Target $11.00

AllianceGlobalPartners
Price Target $4.50

**www.canfite.com**
info@canfite.com